“What the 4-year data from the MURANO [trial] gives clinicians treating chronic lymphocytic leukaemia (CLL) is confidence that in a majority of patients durable disease control is possible after treatment cessation,”1 notes Professor John Seymour, MURANO lead investigator, Director of the Department of Haematology at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital. The ...
MURANO trial continues to give confidence in time-limited therapy for relapsed/refractory CLL
22 Jan 2020
Sponsored by AbbVie Pty Ltd